Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Vineetha Koroth Edavana, Xinfeng Yu, Ishwori B. Dhakal, Suzanne Williams, Baitang Ning, Ian T. Cook, David Caldwell, Charles N. Falany, Susan Kadlubar

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Fulvestrant (Faslodex™) is a pure antiestrogen that is approved to treat hormone receptor-positive metastatic breast cancer in postmenopausal women. Previous studies have demonstrated that fulvestrant metabolism in humans involves cytochromes P450 and UDP-glucuronosyltransferases (UGTs). To date, fulvestrant sulfation has not been characterized. This study examined fulvestrant sulfation with nine recombinant sulfotransferases and found that only SULT1A1 and SULT1E1 displayed catalytic activity toward this substrate, with Km of 4.2 ± 0.99 and 0.2 ± 0.16 μM, respectively. In vitro assays of 104 human liver cytosols revealed marked individual variability that was highly correlated with β-naphthol sulfation (SULT1A1 diagnostic substrate; r = 0.98, P, 0.0001), but not with 17β-estradiol sulfation (SULT1E1 diagnostic substrate; r = 0.16, P = 0.10). Fulvestrant sulfation was correlated with both SULT1A1*1/2 genotype (P value = 0.023) and copy number (P, 0.0001). These studies suggest that factors influencing SULT1A1/1E1 tissue expression and/or enzymatic activity could influence the efficacy of fulvestrant therapy.

Original languageEnglish (US)
Pages (from-to)137-145
Number of pages9
JournalPharmacogenomics and Personalized Medicine
Volume4
Issue number1
StatePublished - 2011
Externally publishedYes

Fingerprint

Cytosol
Liver
Sulfotransferases
Naphthols
Glucuronosyltransferase
Estrogen Receptor Modulators
fulvestrant
Cytochrome P-450 Enzyme System
Estradiol
Genotype
Hormones
Breast Neoplasms

Keywords

  • Copy number
  • Fulvestrant
  • Genotype
  • Sulfotransferase

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Edavana, V. K., Yu, X., Dhakal, I. B., Williams, S., Ning, B., Cook, I. T., ... Kadlubar, S. (2011). Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1. Pharmacogenomics and Personalized Medicine, 4(1), 137-145.

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1. / Edavana, Vineetha Koroth; Yu, Xinfeng; Dhakal, Ishwori B.; Williams, Suzanne; Ning, Baitang; Cook, Ian T.; Caldwell, David; Falany, Charles N.; Kadlubar, Susan.

In: Pharmacogenomics and Personalized Medicine, Vol. 4, No. 1, 2011, p. 137-145.

Research output: Contribution to journalArticle

Edavana, VK, Yu, X, Dhakal, IB, Williams, S, Ning, B, Cook, IT, Caldwell, D, Falany, CN & Kadlubar, S 2011, 'Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1', Pharmacogenomics and Personalized Medicine, vol. 4, no. 1, pp. 137-145.
Edavana, Vineetha Koroth ; Yu, Xinfeng ; Dhakal, Ishwori B. ; Williams, Suzanne ; Ning, Baitang ; Cook, Ian T. ; Caldwell, David ; Falany, Charles N. ; Kadlubar, Susan. / Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1. In: Pharmacogenomics and Personalized Medicine. 2011 ; Vol. 4, No. 1. pp. 137-145.
@article{1ca67559ad684396bd0a34194e4a801f,
title = "Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1",
abstract = "Fulvestrant (Faslodex™) is a pure antiestrogen that is approved to treat hormone receptor-positive metastatic breast cancer in postmenopausal women. Previous studies have demonstrated that fulvestrant metabolism in humans involves cytochromes P450 and UDP-glucuronosyltransferases (UGTs). To date, fulvestrant sulfation has not been characterized. This study examined fulvestrant sulfation with nine recombinant sulfotransferases and found that only SULT1A1 and SULT1E1 displayed catalytic activity toward this substrate, with Km of 4.2 ± 0.99 and 0.2 ± 0.16 μM, respectively. In vitro assays of 104 human liver cytosols revealed marked individual variability that was highly correlated with β-naphthol sulfation (SULT1A1 diagnostic substrate; r = 0.98, P, 0.0001), but not with 17β-estradiol sulfation (SULT1E1 diagnostic substrate; r = 0.16, P = 0.10). Fulvestrant sulfation was correlated with both SULT1A1*1/2 genotype (P value = 0.023) and copy number (P, 0.0001). These studies suggest that factors influencing SULT1A1/1E1 tissue expression and/or enzymatic activity could influence the efficacy of fulvestrant therapy.",
keywords = "Copy number, Fulvestrant, Genotype, Sulfotransferase",
author = "Edavana, {Vineetha Koroth} and Xinfeng Yu and Dhakal, {Ishwori B.} and Suzanne Williams and Baitang Ning and Cook, {Ian T.} and David Caldwell and Falany, {Charles N.} and Susan Kadlubar",
year = "2011",
language = "English (US)",
volume = "4",
pages = "137--145",
journal = "Pharmacogenomics and Personalized Medicine",
issn = "1178-7066",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

AU - Edavana, Vineetha Koroth

AU - Yu, Xinfeng

AU - Dhakal, Ishwori B.

AU - Williams, Suzanne

AU - Ning, Baitang

AU - Cook, Ian T.

AU - Caldwell, David

AU - Falany, Charles N.

AU - Kadlubar, Susan

PY - 2011

Y1 - 2011

N2 - Fulvestrant (Faslodex™) is a pure antiestrogen that is approved to treat hormone receptor-positive metastatic breast cancer in postmenopausal women. Previous studies have demonstrated that fulvestrant metabolism in humans involves cytochromes P450 and UDP-glucuronosyltransferases (UGTs). To date, fulvestrant sulfation has not been characterized. This study examined fulvestrant sulfation with nine recombinant sulfotransferases and found that only SULT1A1 and SULT1E1 displayed catalytic activity toward this substrate, with Km of 4.2 ± 0.99 and 0.2 ± 0.16 μM, respectively. In vitro assays of 104 human liver cytosols revealed marked individual variability that was highly correlated with β-naphthol sulfation (SULT1A1 diagnostic substrate; r = 0.98, P, 0.0001), but not with 17β-estradiol sulfation (SULT1E1 diagnostic substrate; r = 0.16, P = 0.10). Fulvestrant sulfation was correlated with both SULT1A1*1/2 genotype (P value = 0.023) and copy number (P, 0.0001). These studies suggest that factors influencing SULT1A1/1E1 tissue expression and/or enzymatic activity could influence the efficacy of fulvestrant therapy.

AB - Fulvestrant (Faslodex™) is a pure antiestrogen that is approved to treat hormone receptor-positive metastatic breast cancer in postmenopausal women. Previous studies have demonstrated that fulvestrant metabolism in humans involves cytochromes P450 and UDP-glucuronosyltransferases (UGTs). To date, fulvestrant sulfation has not been characterized. This study examined fulvestrant sulfation with nine recombinant sulfotransferases and found that only SULT1A1 and SULT1E1 displayed catalytic activity toward this substrate, with Km of 4.2 ± 0.99 and 0.2 ± 0.16 μM, respectively. In vitro assays of 104 human liver cytosols revealed marked individual variability that was highly correlated with β-naphthol sulfation (SULT1A1 diagnostic substrate; r = 0.98, P, 0.0001), but not with 17β-estradiol sulfation (SULT1E1 diagnostic substrate; r = 0.16, P = 0.10). Fulvestrant sulfation was correlated with both SULT1A1*1/2 genotype (P value = 0.023) and copy number (P, 0.0001). These studies suggest that factors influencing SULT1A1/1E1 tissue expression and/or enzymatic activity could influence the efficacy of fulvestrant therapy.

KW - Copy number

KW - Fulvestrant

KW - Genotype

KW - Sulfotransferase

UR - http://www.scopus.com/inward/record.url?scp=83755194865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83755194865&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:83755194865

VL - 4

SP - 137

EP - 145

JO - Pharmacogenomics and Personalized Medicine

JF - Pharmacogenomics and Personalized Medicine

SN - 1178-7066

IS - 1

ER -